Healio (3/6, Demko) reports, “Among children and teenagers with major depressive disorder [MDD], those with comorbid dysthymia and higher levels of residual symptoms after acute treatment are at greater risk for relapse,” researchers concluded in a study involving “102 youth aged 7 to 18 years with major depression who responded to 12 weeks of fluoxetine and then were randomly assigned to continue or switch to placebo for six more months.” The findingswere published online Feb. 20 in the Journal of Clinical Psychiatry.
Related Links:
— “Depression severity at baseline, end of treatment predict relapse among youth,” Kennard BD, et al., Healio, March , 2018.